Posted in | News | Nanomedicine | Nanobusiness

CEA-Leti and Capsum Announce First Commercial Use of Lipidots Nanovector Technology

CEA-Leti and Capsum today announced that the successful transfer of Leti’s patented Lipidots® nanovector technology to Capsum for cosmetic applications has produced the first commercial use of the new technology.

Lipidots® is a versatile nano-delivery platform based on tiny droplets of oil for encapsulating and carrying drugs or fluorescent imaging agents to targeted cells in the body for treatment or diagnosis. Leti’s partnership with Capsum shows that the technology is easily adapted for applications in the cosmetics industry.

Capsum adapted the Lipidots® technology for its NeoGoutttesTM, nano-emulsions that are used as a component in finished products and that provide a very efficient way of vectorizing lipophilic or hydrophilic concentrates of active ingredients. The nanovector encapsulation protects active ingredients, so they are conveyed through the skin for optimal effect.

“Technology transfer to our partners for commercialization of our research results is a critical part of Leti’s mission,” said Patrick Boisseau, head of Leti’s nanomedicine program. “The success of our project with Capsum demonstrates that the Lipidots® nanovector technology can be scaled up from laboratory to industrial production easily and efficiently, and that it is well suited for a non-medical application like cosmetics.”

“Capsum is focused on providing innovative ways to design and develop cosmetics by incorporating the best science within creative product design,” said Sébastien Bardon, Capsum CEO. “Leti’s Lipidots® technology is a breakthrough that strongly enhances our encapsulation systems, and offers more ways for our customers to bring their products to market.”

The successful technology transfer follows more than seven years of collaboration between Leti and Capsum that included development work on Lipidots®.

This successful technology transfer is the second recent announcement about Lipidots®. In July, Leti announced €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815™. LipImage 815™ is a fluorescent imaging agent based on Lipidots® that carries a fluorescent substance to targeted cells. It will be used to test for early stages of liver cancer

About CEA-Leti

By creating innovation and transferring it to industry, Leti is the bridge between basic research and production of micro- and nanotechnologies that improve the lives of people around the world. Backed by its portfolio of 2,200 patents, Leti partners with large industrials, SMEs and startups to tailor advanced solutions that strengthen their competitive positions. It has launched more than 50 startups. Its 8,000m² of new-generation cleanroom space feature 200mm and 300mm wafer processing of micro and nano solutions for applications ranging from space to smart devices. Leti’s staff of more than 1,700 includes 200 assignees from partner companies. Leti is based in Grenoble, France, and has offices in Silicon Valley, Calif., and Tokyo.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    CEA-Leti. (2019, February 11). CEA-Leti and Capsum Announce First Commercial Use of Lipidots Nanovector Technology. AZoNano. Retrieved on May 24, 2024 from

  • MLA

    CEA-Leti. "CEA-Leti and Capsum Announce First Commercial Use of Lipidots Nanovector Technology". AZoNano. 24 May 2024. <>.

  • Chicago

    CEA-Leti. "CEA-Leti and Capsum Announce First Commercial Use of Lipidots Nanovector Technology". AZoNano. (accessed May 24, 2024).

  • Harvard

    CEA-Leti. 2019. CEA-Leti and Capsum Announce First Commercial Use of Lipidots Nanovector Technology. AZoNano, viewed 24 May 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.